Patients
Clinical Trials
At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders and pulmonary diseases.
- Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling. The U.S. Food and Drug Administration has approved REBLOZYL® (luspatercept-aamt) for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell (RBC) transfusions and for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
- In our pulmonary program, we are developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling patients in the Phase 2 SPECTRA trial.
The clinical trials listed below are Acceleron or partner-sponsored trials, some of which are actively recruiting patients. Each trial in the list contains a link to clinicaltrials.gov, where you will find a full description and contact information.
Clinical Trial Transparency: Acceleron is committed to public health and scientific exchange. As a part of this commitment, we make our clinical trial information accessible so that patients, health care providers, and the general public are included in the conversation. Click here to learn more about Acceleron’s Policy on Clinical Trial Transparency.
| Drug | Study Phase | Disease |
|---|---|---|
| Luspatercept | COMMANDS Phase III* | Low or Intermediate Risk MDS |
| Luspatercept | BEYOND Phase II* | Beta-Thalassemia |
| Luspatercept | Phase II* | Myelofibrosis |
| Luspatercept | Phase II Extension | MDS |
| Luspatercept | Phase II Extension | Beta-Thalassemia |
| Luspatercept | Phase II | Anemia in Lower-Risk MDS |
| Luspatercept | Phase II | Beta-Thalassemia |
| Sotatercept | PULSAR Phase II | Pulmonary Arterial Hypertension |
| Sotatercept | SPECTRA Phase II | Pulmonary Arterial Hypertension |
| Acceleron trials listed as recruiting or active on www.clinicaltrials.gov | ||
* Bristol-Myers Squibb-sponsored